TNF-Alpha Inhibitors Will Continue To Dominate First- And Second-Line Biologic Therapy For The Treatment Of Rheumatoid Arthritis Through 2011
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established branded drugs such as, Centocor...